Telomir Pharmaceuticals, Inc. (TELO) Form S-3 — Oct 27, 2026
Telomir Pharmaceuticals filed an S-3 registering the resale of up to 5,292,810 shares held by selling securityholders, including 4,900,750 shares sold in an October 2026 private placement and 392,060 warrant shares held by placement agent Alexander Capital. The private placement raised approximately $5.6 million in gross proceeds at $1.16 and $1.13 per share. The company receives no proceeds from any resale by the selling securityholders, so this filing is not itself dilutive, but it creates a meaningful share overhang of roughly 7% of the 73.7 million shares outstanding.
Key figures
- Gross Proceeds
- 5600000
- Offering Price
- $1.16 and $1.13 per share (private placement prices)
- Shares Offered
- 5292810
- Shares Outstanding
- 73675706
- Placement agent fee
- $460,850
- Last reported sale price
- $1.01 (October 26, 2026)
- Private placement price 1
- $1.16
- Private placement price 2
- $1.13
- Private placement shares sold
- 4843303
- Placement agent warrant shares
- 392060
- Private placement shares second
- 57447
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.